Free Trial
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Fulcrum Therapeutics logo
$6.88 +0.36 (+5.52%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$6.88 +0.00 (+0.01%)
As of 08/22/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Key Stats

Today's Range
$6.45
$6.92
50-Day Range
$6.34
$8.01
52-Week Range
$2.32
$9.90
Volume
362,286 shs
Average Volume
984,909 shs
Market Capitalization
$372.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.57
Consensus Rating
Moderate Buy

Company Overview

Fulcrum Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

FULC MarketRank™: 

Fulcrum Therapeutics scored higher than 19% of companies evaluated by MarketBeat, and ranked 859th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Fulcrum Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Fulcrum Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fulcrum Therapeutics is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fulcrum Therapeutics is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fulcrum Therapeutics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.98% of the float of Fulcrum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulcrum Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Fulcrum Therapeutics has recently increased by 2.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Fulcrum Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Fulcrum Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.98% of the float of Fulcrum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulcrum Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Fulcrum Therapeutics has recently increased by 2.03%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Fulcrum Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulcrum Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Fulcrum Therapeutics is held by insiders.

  • Percentage Held by Institutions

    89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulcrum Therapeutics' insider trading history.
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FULC Stock News Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.tc pixel
FULC Fulcrum Therapeutics, Inc. - Seeking Alpha
See More Headlines

FULC Stock Analysis - Frequently Asked Questions

Fulcrum Therapeutics' stock was trading at $4.70 at the start of the year. Since then, FULC shares have increased by 46.4% and is now trading at $6.88.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its earnings results on Tuesday, July, 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01.

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Top institutional investors of Fulcrum Therapeutics include Adage Capital Partners GP L.L.C. (8.48%), Nantahala Capital Management LLC (7.93%), Balyasny Asset Management L.P. (2.47%) and Geode Capital Management LLC (2.21%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould and Greg Tourangeau.
View institutional ownership trends
.

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
7/29/2025
Today
8/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FULC
CIK
1680581
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$2.00
Potential Upside/Downside
+10.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.73 million
Net Margins
N/A
Pretax Margin
-0.64%
Return on Equity
-31.05%
Return on Assets
-28.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
24.42
Quick Ratio
24.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.96 per share
Price / Book
1.74

Miscellaneous

Outstanding Shares
54,092,000
Free Float
50,306,000
Market Cap
$372.15 million
Optionable
Optionable
Beta
2.47

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:FULC) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners